Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03800563 · ClinicalTrials.gov registry record · NA
Laser Assisted Liposuction and Facial Autologous Fat Grafting With the LipoLife System
A NA study of Laser Assisted Liposuction, sponsored by Alma Lasers.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT03800563 is a NA study of Laser Assisted Liposuction that has completed, run by Alma Lasers. The registered enrollment target is 20 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03800563, a NA study of Laser Assisted Liposuction, has completed, sponsored by Alma Lasers.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
Multi-center, prospective, open-label, single arm study. The study aims to evaluate the safety and efficacy of Laser Assisted Liposuction procedure performed with the LipoLife system. The study will include twenty (20) eligible subjects, that are willing to undergo abdominal or outer thighs laser-assisted liposuction. Five to twenty (5-20) subjects out of this study group should also be eligible for facial fat grafting. Follow up visits to evaluate study endpoints will take place at 1, 3 and 6 months after the surgery.
Conditions Studied
Interventions
- DEVICE LipoLife system
Study Locations (2)
Florida
- Sanctuary Plastic Surgery - Boca Raton
Other
- Yitzhak Shamir Medical Center - Be’er Ya‘aqov
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-11-06 |
| Est. Completion | 2020-05-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03800563
The ClinicalTrials.gov registry entry for NCT03800563 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alma Lasers, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Laser Assisted Liposuction appearing as the primary indexed condition, and to 1 intervention - of which LipoLife system is the first listed.
NCT03800563 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Other.
Frequently Asked Questions
What is clinical trial NCT03800563 about?
NCT03800563 is a clinical study titled "Laser Assisted Liposuction and Facial Autologous Fat Grafting With the LipoLife System". Multi-center, prospective, open-label, single arm study. The study aims to evaluate the safety and efficacy of Laser Assisted Liposuction procedure performed with the LipoLife system. The study will include twenty (20) eligible subjects, that are willing to undergo abdominal or outer thighs laser-as...
What is the current status of trial NCT03800563?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2018-11-06. Estimated completion is 2020-05-20.
What conditions does trial NCT03800563 study?
This clinical trial studies the following conditions: Laser Assisted Liposuction.
What interventions are being tested in trial NCT03800563?
The interventions under investigation include: LipoLife system (DEVICE).
Who is sponsoring clinical trial NCT03800563?
This trial is sponsored by Alma Lasers, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03800563 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.